For generic pharma manufacturers, getting a clear picture of the UK market has always been tricky. Data arrives from multiple sources, in different formats, at different times – and by the time it’s been pulled together, the window for a fast decision has often closed.
This is one reason we do what we do. Pharmly® brings together over 20 million pharmaceutical market data points a month, giving clients a single, live view of the market that would be impossible to build from internal data alone.
Here are the main ways it’s supporting our clients:
Supporting business development and licensing
One of the most common use cases is identifying growth opportunities. Clients use Pharmly to track competitor activity, spot gaps in the market and pinpoint products worth pursuing, whether for development, licensing or acquisition. Having that intelligence in one place, updated in real time, means business development teams can build stronger cases and move faster.
Managing portfolios with greater confidence
Portfolio decisions are only as good as the data behind them. Pharmly helps clients see where healthcare providers are over- or underspending, assess how their existing products are performing across the market, and model what a stronger portfolio could look like. Rather than piecing this together from spreadsheets and disparate reports, it’s all visible in one system.
Staying ahead of medication shortages
Supply chain disruptions are an ongoing reality for generic manufacturers. Pharmly gives clients early visibility of developing UK medication shortages so they can plan – whether that means increasing manufacture, adjusting imports, or repositioning existing stock. Acting early rather than reacting late makes a big difference.
Pricing with clarity
Pricing in generics is tightly regulated and highly competitive. Pharmly Pricing lets clients analyse their brand prices across the market, understand where their pricing sits relative to the competition, and find the pricing sweet spot – one that maintains compliance and affordability while protecting margins where conditions allow.
Demonstrating savings for the NHS
For clients pursuing brand switches, Pharmly’s budget impact modelling helps them build the case for integrated care boards (ICBs). They can clearly and credibly show where switching to a cheaper, bioequivalent alternative would generate meaningful NHS savings, which in turn opens doors commercially.
Monitoring secondary care trends
Hospital and other specialist care data is notoriously hard to access and interpret. Pharmly gives clients a window into secondary care activity across England at the NHS Trust level, helping them prepare for tenders, spot regional usage hotspots, and understand where demand for their products is growing.
A joined-up picture
What runs through all these use cases is the same need: reliable, timely data that’s easy to understand and easy to share. Pharmly brings that together in one place, so manufacturers spend less time gathering information and more time acting on it.
To find out more or book a demo, please get in touch at info@analytichealth.co.uk.